

**Synairgen plc**

**("Synairgen" or the "Company")**

**Holding(s) in Company**

**Southampton, UK,:** Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was informed on 21 August 2020 that Leonard Licht, a private investor, now holds 7,375,000 ordinary shares of 1 pence each in the capital of the Company, representing 4.93% of the Company's issued share capital.

Enquiries:

<b>Synairgen plc</b>	+44 (0) 23 8051 2800
Richard Marsden ( <i>Chief Executive Officer</i> ) John Ward ( <i>Finance Director</i> )	
<b>finnCap - nominated adviser and broker</b>	+44 (0) 20 7220 0500
Geoff Nash, Kate Bannatyne, Charlie Beeson ( <i>Corporate Finance</i> ) Alice Lane, Manasa Patil ( <i>ECM</i> )	
<b>Consilium Strategic Communications - financial media and investor relations adviser</b>	+44 (0) 20 3709 5700
Mary-Jane Elliott, Sue Stuart, Olivia Manser	